History & Milestones

BIOMEX
History & Milestones.
This is our DNA.

Our consistent and dependable supply of both positive and negative plasma has established us as a valued partner in the diagnostic industry for many years. Since the day of the foundation, BIOMEX DNA has been growing, with each piece of history we become better.

"Every cornerstone of our growth, every person, every spark of a brilliant idea, has made BIOMEX what it is today."

Oliver Bošnjak | General Manager

Our History. Our DNA.

Current milestones
of our quality management

BIMEX in Short

Our mission: To solve the sourcing problem for our customers
We solve problems for our customers that go far beyond the pure supply of products. We procure clinical samples worldwide, such as chikungunya samples from freshly infected people in Africa, all the HIV subtypes and also progressive samples from Lyme disease patients.
Unique infrastructure
We sample over 90% of the plasmas ourselves in our plasma centers in Heidelberg and Munich, as well as in our mobile donation center in Cameroon (Africa). As a customer, you have real-time online access to our entire sample inventory via our SampleShop, consisting of over 600,000 blood and plasma samples, as well as more than 50,000 FFPE tissue blocks.
Quality services
In addition, we also offer a wide range of services including the complete implementation of tests according to CTS / CS for products in List A (IVDD) or Class D and C (IVDR), the creation of test protocols and reports, the determination of stability data, the manufacture of lot release panels, and much, much more.

Since 2019, BIOMEX has had a special permit to export Disease State Plasma and patient samples to China.
Previous
Next

MORE THAN

0
PBMC Samples
100000
Remnant Lab Samples
0
Characterized FFPE Blocks
1989

Founding of BIOMEX headquartered in Mannheim.
 

2004

2004 – Oliver Bošnjak, who has degrees in chemistry and business administration, becomes managing partner of BIOMEX.

 

Oliver Bošnjak
2005

Certification of BIOMEX according to DIN EN ISO 9001:2000.

 

2006

Founding of the Plasma Center in Munich and certification according to ISO 9001:2000. The main focus of the Plasma Center in Munich is the production of disease state plasma for diagnostic purposes.

2006 – Founding of the Plasma Center in Munich and certification according to ISO 9001:2000. The main focus of the Plasma Center in Munich is the production of disease state plasma for diagnostic purposes.
2007

Expansion of the Plasma Center for the production of specific normal plasma with a production capacity of 25,000 liters p.a.

 

2008

Move to one of our own buildings of 1200 m² and set up of a company laboratory. Employment of 30 staff.

2009

Opening of the Heidelberg Plasma Center to expand the donation capacity of plasmas for diagnostic purposes.

 

2009 – Opening of the Heidelberg Plasma Center to expand the donation capacity of plasmas for diagnostic purposes.
2010

Expansion of the laboratory area to 110 m2 and acquisition of an operating license for a microbiological L2 laboratory according to DIN 58956-3. Recertification according to DIN EN ISO 9001:2008.

2011

Establishment of a mobile donation center, for the collection of patient samples, in West Africa. 

2011 – Establishment of a mobile donation center, for the collection of patient samples, in West Africa. Certification of BIOMEX according to DIN EN ISO 13485:2003. Founding of the sister company DiaMex GmbH as a supplier of manufacturer-independent controls.
2012

Expansion of the laboratory surface area to 230 m².

2012 ­– Expansion of the laboratory surface area to 230 m².
2013

Founding of the sister company ESfEQA GmbH as an accredited provider of external round robin tests.

2013 ­– Founding of the sister company ESfEQA GmbH as an accredited provider of external round robin tests.
2014

Implementation of contract studies for the approval of IVD products (list A, B and others). Start of sales in China by sales partners.

2015

New in the portfolio: Prospective clinical sampling according to ICH guidelines.

 
2015 – New in the portfolio: Prospective clinical sampling according to ICH guidelines.
2016

Expansion of the product portfolio to include panels from the company ZeptoMetrix.

2017

Acquisition of an operating license for an L3 ** laboratory compliant with DIN 58956-3 and establishment of a worldwide network of distributors.

2017 – Acquisition of an operating license for an L3 ** laboratory compliant with DIN 58956-3 and establishment of a worldwide network of distributors.
2018

Start of the online Sampleshop with real-time access to the entire sample inventory of BIOMEX, sample reservation and automatic offer generation.

2018 – Start of the online Sampleshop with real-time access to the entire sample inventory of BIOMEX, sample reservation and automatic offer generation.
2018

We opened our Chinese subsidiary Neckar Biotechnology in Shanghai .

2018 – We opened our Chinese subsidiary Neckar Biotechnology in Shanghai .
2019

Expansion of laboratory capacity to 600 m2. Establishment of the company’s own, sealed rooms for external companies to carry out contract studies. Implementation of prospective clinical sampling in accordance with DIN EN ISO14155: 2020.

2020

The year of Covid.

As the first supplier worldwide: Acquisition of large amounts of plasma from recovered covid patients (over 3000 plasma units) and provision to the IVD industry for the production of antibody tests.

Collection of over 8000 smears from SARS-Covid-positive individuals at the beginning of the second covid wave. Establishment as the largest validation provider for coronavirus antigen tests and coronavirus antigen rapid tests.

Establishment of a fully functional L2 laboratory to process up to 3,000 PCR tests per day. 

Recertification according to DIN EN ISO 9001:2015.
2021

Expansion, Management & SARS Cov2 antigen tests.

Further expansion of laboratory capacities: in order to be able to handle the constantly high demand from the diagnostic industry, BIOMEX continues to expand the laboratory area.

Establishment as the largest validation provider of SARS Cov2 antigen tests and rapid tests with over 70 validation studies completed.

Strengthening of the management team by Dr. Klaus Esperschidt, who is responsible for the Operations division as Managing Director.
2022

We grow: Acquisition of Atreide Biosamples – Corona rapid test validation – Opening of the Chinese subsidiary – Join our Journey – Expansion of the product portfolio

We grow: Acquisition of Atreide Biosamples, a recognized specialist in the sourcing of tumorous tissue samples for the life science industry.

BIOMEX successfully completes the 155th SARSCov2 Corona rapid test validation BIOMEX successfully completes the 155th SARSCov2 Corona rapid test validation, becoming the company with the highest number of Corona assay validations.

Opening of the Chinese subsidiary – Neckar Biotechnology – in Shanghai.

Launch of the new campaign “Join our Journey”, which communicates the progress of BIOMEX in the new segments.

Expansion of the product portfolio to include tissue, PBMC`s and cfDNA to serve the LifeScience industry.

The Future is now. Come back soon.